Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7417774 | 0.82 | TSHR (0.48) | TSHRALDH1A1TDP1MEN1LMNA | |
| SCHEMBL698511 | 0.81 | MAPT (0.42) | TSHRALDH1A1MAPT | |
| SCHEMBL4203569 | 0.80 | TSHR (0.47) | TSHRALDH1A1TDP1MEN1LMNA | |
| SCHEMBL285034 | 0.80 | TSHR (0.57) | TSHRALDH1A1TDP1MEN1LMNA | |
| SCHEMBL25435787 | 0.80 | TSHR (0.54) | TSHRALDH1A1TDP1MEN1LMNA | |
| SCHEMBL37351 | 0.80 | TSHR (0.54) | TSHRALDH1A1TDP1MEN1LMNA | |
| SCHEMBL697642 | 0.78 | CA1 (0.41) | TSHRALDH1A1TDP1LMNAKMT2A | |
| SCHEMBL22556013 | 0.78 | PRKCA (0.30) | — | |
| SCHEMBL6896110 | 0.78 | TSHR (0.40) | TSHRALDH1A1TDP1LMNACYP3A4 | |
| SCHEMBL451856 | 0.78 | TSHR (0.45) | TSHRALDH1A1TDP1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2189443-B1 | TRICYCLIC AMIDE COMPOUND | RES FOUND ITSUU LAB (JP) | 2013-10-23 | — | — | EP | claimed |
| US-7687490-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2010-03-30 | — | — | US | claimed |
| EP-1870412-A1 | 2-THIOETHENYL CARBAPENEM DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 2007-12-26 | — | — | EP | claimed |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-01-04 | — | — | US | claimed |
| US-5616600-A | Griseolic acid compounds and their use as a phosphodiesterase inhibitor | SANKYO COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | claimed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| US-5480987-A | 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them | AMERICAN CYANAMID COMPANY (US) | 1996-01-02 | — | — | US | claimed |
| US-5369102-A | B-lactamase inhibitors | AMERICAN CYANAMID COMPANY (US) | 1994-11-29 | — | — | US | claimed |
| EP-0478874-A2 | Novel 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them | AMERICAN CYANAMID COMPANY (US) | 1992-04-08 | — | — | EP | claimed |
| US-5068232-A | Bactericides | AMERICAN CYANAMID COMPANY (US) | 1991-11-26 | — | — | US | claimed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2023-07-13 | — | — | US | disclosed |
| EP-4138923-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar, S.A. (ES) | 2023-03-01 | — | — | EP | disclosed |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2023-01-19 | — | — | US | disclosed |
| EP-0165384-A1 | Carbapenem derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1985-12-27 | — | — | EP | disclosed |
| US-4552873-A | BACTERICIDES | SANKYO COMPANY LIMITED (JP) | 1985-11-12 | — | — | US | disclosed |
| US-4395418-A | 6-HYDROXYETHYL SUBSTITUTED ANTIBIOTICS | SANKYO COMPANY LIMITED (JP) | 1983-07-26 | — | — | US | disclosed |
| EP-0072710-A1 | Carbapenem derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1983-02-23 | — | — | EP | disclosed |
| EP-0069373-A1 | (5R, 6R)-Penem compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, BPGM | TSHR 1341/4885ALDH1A1 1182/4885TDP1 3001/4885 |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | TSHR 1530/4885ALDH1A1 785/4885TDP1 1196/4885 |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | HDGF, XPOT, TXLNA | TSHR 1620/4885ALDH1A1 1158/4885TDP1 1388/4885 |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | B3GAT3, MGAT3, SDAD1 | TSHR 1572/4885ALDH1A1 162/4885TDP1 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.